Member Info for stephen11

Look up Glassdoor for the salary of a Iceland or Spar Manager - you'll see my estimations are correct.

- Go to the home page of the HL portal

- Below the secure messages section on the right hand side, click VIEW SHAREHOLDER MEETINGS

- Then on GDR, click GIVE INSTRUCTIONS and vote as you see fit

- I am off a similar opinion that the salaries of the CEO and CFO are excessive (even with a 20% reduction) when you consider GDR has a head count of around 35 staff - its by no means a large multinational.

- A supermarket manager of mid-size store with a sales turnover of £4m gets around £40-£50 thousand these days (for managing 50 staff)

- Additionally, sales revenue will be around £1m - Russ Shaw hasn't exactly had to manage a large sales ledger.

- And, we were at 1.5p in June 2025 and the board had full sight of the cash runway

- Why wasn't a placing organised at this higher SP in June, instead of the CEO/CFO attempting a placing at 0.02p. This was a missed opportunity

- And, why do the CEO/CFO get paid more than some European Prime-Ministers? Are they worth it?

Just my spin on things as a long term holder - others may have different opinions and i respect that.

GLA.

Stephen11.

Conversely, DN's average may be higher, as from memory in one of his earlier posts he stated being a shareholder for 3/4 years.

Let's not forget, for instance that the share price was 43p in March 2023 (who knows what he bought the first 20m for - anything between 1.5-43p is possible.

The reality is that none of us know his true average.

Anyone - i still don't think he'll vote yes for a low-ball SP fundraise - i certainly won't.

That's my point.

I wouldn’t be too sure about there being a large discounted placing Jimi - yes funding is needed, although I can’t see David Nugent voting for a raise that significantly dilutes his large holding. It just doesn’t make sense. Gino and Russ did explicitly mention large shareholders were being consulted regarding future funding requirements.

If anything we are in a stronger position now than the ill-fated attempted rise at 0.02p.

The current cash burn 🔥 is £350 000 - £4.2 million in late Feb/March would carry us to March 2027, by which time it is hoped FDA would be well under way.

A placing above 1p is more likely.

It was eluded to in the meeting that DN has signed an NDA. I’m guessing that by taking equity he is confidant of a significant return in the future. This is an extremely positive indicator and suggests DN likes what he see’s under the bonnet.

E.g., near term news and commercial traction.

Thankyou Amers - especially for your positivity in the dark days when we were at 0.02p and for helping to rally the ‘no’ vote.

Much brighter days ahead - I agree with your valuation predictions. We are at a point of inflection, and turning from a small player into a larger company with near term commercial traction on the way.

Sir David Nugent has a nice ring to it.

Amers my friend - Mr. Slacker has appeared as a green box to me for a long time...LOL

In a nutshell:

- A £1m shareholder loan from major holder David Nugent, providing immediate runway extension to February 2026 with the option of a second tranche later.

- The first £500k carries no fees or interest, and Nugent has stated his intention to convert all drawn funds into equity in a future raise, making the structure explicitly non-predatory and strongly aligned with shareholders.

- The secured loan stabilises near-term finances while signalling confidence from a key strategic investor.

- What's not to like!

GLA.

Stephen11.

I noticed this aswell Muminr - I thought they alluded to speaking to more than one shareholder about financing in general. I took it to mean that they want to get large existing shareholders onboard I.e., to avoid another No vote.

I’d hope any future fundraises were above 1p at least.

We do need cash from somewhere before April 2026.

Interesting that NDAs have also been signed.

Unsurprisingly, direct questions must have been filtered and put in file 13?

Sir Ian’s statement emphasised that under-capitalised UK life-science companies are often forced into early buyouts, referencing his previous exits at Axis-Shield and Horizon Discovery. With Genedrive now entering commercial scale-up, could you clarify how the Board is thinking about strategic alternatives — whether partnership, licensing, or acquisition — should the UK capital environment continue to lag?

45 mins in and cash flow not mentioned yet?

Thanks Amers 👍

Thanks Lionel1.

Did the results RNS allude to another ii? And how was it worded?

I’d check myself, although I’m away on a Xmas mini break - no laptop with me. Driving home after breakfast and will hopefully make the 2pm meeting.

I was hoping for a confirmation of loan RNS today?

The powers that be don’t seem to be able to distinguish a good thing when they see it. Two World 🌍 class tests screaming out for UK adoption. Health economics and cost savings proven.

At that price i'd be living on a cruise ship Eureka...lol.

Good points Choochie. Eureka - i respectfully disagree

Trade sales happen at inflection points, not at peaks.

GDR is:

- Scientifically derisked (Positive)

- Commercially validated (Positive)

- Strategically positioned (Positive)

- Financially constrained (Negative)

This combination is exactly when large diagnostics companies buy.

If the following happen in early 2026 a trade sale might look quite lucrative to a big pharma company:

- Runway extended into 2026

- Scotland rollout revenue established

- Growing NHS adoption

- Some Middle East traction

- FDA in process

- Buyer sees a stable, de-risked asset but not explosive growth yet

###An INFLECTION point###

- Additionally, previous behaviour is often a predictor of future behaviour

- Gilham is an astute business man and a hard negotiator with a history of delivering big deals in the past

Why has Gilham mentioned this then Eureka? I can’t think of any other logical explanation? 🤔.